Abstract

IntroductionAnifrolumab is a type I interferon (IFN) receptor 1 (IFNAR1) blocking antibody approved for treating patients with systemic lupus erythematosus (SLE). Here, we investigated the immunomodulatory mechanisms of anifrolumab using...

Full Text

Published Version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
A loss‐of‐function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patients
Julien Pothlichet ... Damien Vitour
EMBO Molecular Medicine | VOL. 3
Julien Pothlichet, et. al.Julien Pothlichet ... Damien Vitour
26 Jan 2011
How does interferon‐α insult the vasculature? Let me count the ways
Mariana J Kaplan ... Jane E Salmon
Arthritis & Rheumatism | VOL. 63
Mariana J Kaplan, et. al.Mariana J Kaplan ... Jane E Salmon
28 Jan 2011
Abnormalities of the type I interferon signaling pathway in lupus autoimmunity
Stefania Gallucci ... Ana M Gamero
Cytokine | VOL. 146
Stefania Gallucci, et. al.Stefania Gallucci ... Ana M Gamero
30 Jul 2021
111: Aryl hydrocarbon receptor negatively regulates type I interferon production and the development of murine lupus
Soyoung Lee ... Tadamitsu Kishimoto
Cytokine | VOL. 70
Soyoung Lee, et. al.Soyoung Lee ... Tadamitsu Kishimoto
16 Sep 2014
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
Expert consensus recommendations for the diagnosis and treatment of chronic non-bacterial osteitis (CNO) in adults
Elizabeth M Winter ... Anne T Leerling
Annals of the Rheumatic Diseases | VOL. -
Elizabeth M Winter, et. al.Elizabeth M Winter ... Anne T Leerling
28 Nov 2024
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
Jinjing Liu ... Xiaofeng Zeng
Annals of the Rheumatic Diseases | VOL. -
Jinjing Liu, et. al.Jinjing Liu ... Xiaofeng Zeng
27 Nov 2024
CD-19 CAR-T cells for polyrefractory rheumatoid arthritis
Merav Lidar ... Abraham Avigdor
Annals of the Rheumatic Diseases | VOL. -
Merav Lidar, et. al.Merav Lidar ... Abraham Avigdor
27 Nov 2024
Correction: Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment
-
Annals of the Rheumatic Diseases | VOL. -
--
27 Nov 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.